XBIT

XBiotech Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.19
52-Week Range: $2.09 – $3.44
Market Cap: $66.46M
P/E (TTM): —
EPS (TTM): -1.48
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.52
PEG Ratio: —
Return on Equity: -29.94%
Return on Assets: -19.30%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 33.15
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-28.50M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-42.76M

XBIT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$4.01M	$0.00	$0.00	$0.00
Cost of Revenue	$651.00K	$0.00	—	—
Gross Profit	$3.36M	$0.00	—	—
Research & Development	$31.54M	$32.85M	$37.76M	$47.39M
Selling, General & Admin	$6.30M	$4.66M	$4.71M	$8.29M
Operating Expenses	$37.85M	$37.51M	$42.47M	$55.69M
Operating Income	-$34.49M	-$37.51M	-$42.47M	-$55.69M
EBITDA	-$31.88M	-$22.57M	-$36.01M	-$43.53M
Pretax Income	-$33.59M	-$24.31M	-$38.56M	-$45.30M
Income Tax	-$688.00K	$244.00K	-$32.00K	$235.00K
Net Income	-$32.90M	-$24.56M	-$38.53M	-$45.54M
Diluted EPS	-1.08	-0.81	-1.26	-1.49
Diluted Shares	30.44M	30.44M	30.46M	30.49M

XBIT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$157.31M	$200.02M	$172.68M	$125.55M
Receivables	$1.76M	$935.00K	$858.00K	$360.00K
Current Assets	$219.84M	$201.72M	$174.57M	$126.95M
Total Assets	$246.10M	$226.62M	$199.09M	$150.08M
Current Liabilities	$4.07M	$6.10M	$15.11M	$7.93M
Total Debt	—	—	$10.25M	—
Total Liabilities	$5.70M	$7.77M	$16.82M	$9.73M
Retained Earnings	-$27.75M	-$52.31M	-$90.84M	-$136.38M
Shareholders' Equity	$240.40M	$218.85M	$182.27M	$140.35M
Working Capital	$215.78M	$195.62M	$159.46M	$119.02M

XBIT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$14.82M	-$18.73M	-$30.96M	-$39.92M
Capital Expenditure	-$585.00K	-$362.00K	-$1.30M	-$289.00K
Free Cash Flow	-$15.41M	-$19.09M	-$32.27M	-$40.21M
Depreciation & Amortisation	$2.61M	$1.74M	$1.75M	$1.69M
Stock-Based Compensation	$5.06M	$3.26M	$1.75M	$3.62M
Investing Cash Flow	-$63.89M	$61.50M	-$1.30M	-$289.00K
Financing Cash Flow	$0.00	-$9.00K	$10.45M	-$10.25M
Dividends Paid	$0.00	—	—	—
Net Change in Cash	-$78.72M	$42.76M	-$21.82M	-$50.46M

XBIT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.62M	$5.34M	$5.08M	$25.36M	$5.21M	$5.30M
Selling, General & Admin	$1.93M	$1.00M	$967.00K	$4.40M	$1.07M	$850.00K
Operating Expenses	$13.55M	$6.34M	$6.05M	$29.75M	$6.27M	$6.15M
Operating Income	-$13.55M	-$6.34M	-$6.05M	-$29.75M	-$6.27M	-$6.15M
EBITDA	-$10.32M	-$1.29M	-$5.48M	-$26.44M	-$5.12M	-$6.38M
Pretax Income	-$10.86M	-$1.73M	-$5.91M	-$26.82M	-$5.46M	-$6.68M
Income Tax	$29.00K	$28.00K	$102.00K	$76.00K	$49.00K	$46.00K
Net Income	-$10.88M	-$1.76M	-$6.01M	-$26.89M	-$5.50M	-$6.73M
Diluted EPS	-0.36	-0.06	-0.20	—	-0.18	-0.22
Diluted Shares	30.49M	30.49M	30.49M	—	30.49M	30.49M

XBIT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$155.90M	$152.94M	$147.37M	$125.55M	$115.46M	$109.53M
Receivables	$638.00K	$638.00K	$525.00K	$360.00K	$302.00K	$291.00K
Current Assets	$157.69M	$154.89M	$148.95M	$126.95M	$117.05M	$111.16M
Total Assets	$181.86M	$178.68M	$172.42M	$150.08M	$139.84M	$133.65M
Current Liabilities	$5.41M	$3.86M	$3.56M	$7.93M	$3.00M	$3.35M
Total Liabilities	$7.15M	$5.62M	$5.34M	$9.73M	$4.82M	$5.19M
Retained Earnings	-$101.72M	-$103.48M	-$109.48M	-$136.38M	-$141.88M	-$148.61M
Shareholders' Equity	$174.71M	$173.06M	$167.08M	$140.35M	$135.02M	$128.46M
Working Capital	$152.28M	$151.03M	$145.39M	$119.02M	$114.05M	$107.81M

XBIT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$6.72M	-$5.99M	-$4.26M	-$22.95M	-$8.97M	-$4.51M
Capital Expenditure	-$94.00K	-$51.00K	-$110.00K	-$34.00K	—	—
Free Cash Flow	-$6.81M	-$6.04M	-$4.37M	-$22.99M	-$8.97M	-$4.51M
Depreciation & Amortisation	$442.00K	$439.00K	$427.00K	$378.00K	$332.00K	$302.00K
Stock-Based Compensation	$3.33M	$107.00K	$24.00K	$162.00K	$172.00K	$172.00K
Investing Cash Flow	-$94.00K	-$51.00K	-$110.00K	-$34.00K	$9.00K	-$4.00K
Financing Cash Flow	-$10.25M	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$17.06M	-$6.04M	-$4.37M	-$22.99M	-$8.96M	-$4.52M

Market Snapshot

About

XBiotech Inc. is a biopharmaceutical company focused on discovering and developing True Human monoclonal antibodies for treating a variety of diseases. The company's lead product candidate, bermekimab, is a therapeutic antibody targeting interleukin-1 alpha, being developed for inflammatory conditions including hidradenitis suppurativa and other dermatological diseases. XBiotech utilizes its proprietary True Human antibody discovery platform to develop treatments with potentially reduced immunogenicity.